BioCentury
ARTICLE | Company News

AstraZeneca, Gruenenthal deal

June 6, 2016 7:00 AM UTC

AstraZeneca granted Gruenenthal exclusive rights to Zurampic lesinurad and a fixed-dose combination of Zurampic and allopurinol in Europe and Latin America. In February, the European Commission approved Zurampic to treat hyperuricemia in adults with gout; AZ expects to submit an NDA to FDA this year for the combination therapy. ...